Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others


PsoProtect International Registry

PsoProtect is an international registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. The registry seeks to improve our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis. This information will inform clinicians when assessing risk and treating COVID-19 in patients with psoriasis. 


recent publications on COVID-19 & PSORIASIS

Current guidelines recommend continuing biologic therapy in dermatologic patients who have not tested positive for or exhibited signs/symptoms of COVID-19 and postponing biologic therapy in patients who have tested positive for or exhibited signs/symptoms of COVID-19.^(1-3) In order to help guide current recommendations, we aimed to investigate the incidence and prognostic outcomes of positive SARS-CoV-2 infection in psoriasis patients on biologic therapy.
CONCLUSION: It is particularly crucial to tailor psoriasis care to individual needs in order to protect the physical and mental well-being of patients during the pandemic.
CONCLUSIONS: The COVID-19 pandemic has a negative impact on psoriasis management and healthcare delivery. Dermatologists are cautious about using biologics and immunosuppressive drugs during the pandemic, making case-by-case decisions. Psoriasis patients need compliance monitoring, and psychological support during the pandemic, which can be facilitated by teledermatology.


View all publications from PubMed 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.